On March 6, 2026, Peptide Sciences — the largest US research peptide vendor, with an estimated $7.4 million in monthly revenue — permanently ceased operations. The website is now dark. No orders are being fulfilled. The company posted a brief farewell message thanking customers for their support but provided no detailed explanation for the closure.

For researchers who relied on Peptide Sciences, this guide covers what happened, why it happened, and what comes next.

The Timeline

2023–2024: FDA begins reclassifying peptides, moving several to Category 2 status, restricting compounding pharmacy access. BPC-157 is reclassified in November 2024.

January 2025: The International Trade Commission issues a General Exclusion Order blocking all tirzepatide imports that infringe pharmaceutical trademarks — directly targeting a major revenue category for gray-market research vendors.

September 2025: FDA issues more than 50 warning letters to peptide-related businesses in a single coordinated enforcement wave — the largest such action in the agency’s history against this market segment.

October–November 2025: Third-party testing reveals quality problems at Peptide Sciences. Independent testing platform data shows CJC-1295 averaging 4.3/10 quality score. Retatrutide samples return E ratings with counterfeit detection flags — meaning independent labs could not verify the compound was genuine retatrutide.

December 2025: Peptide Sciences continues operating. Revenue peaks at ~$7.4M for the month.

Early 2026: The SAFE Drugs Act (H.R. 6509) is introduced in Congress. As drafted, it would prohibit research chemical sales of compounds biologically identical to FDA-approved drugs — eliminating the legal framework Peptide Sciences and similar vendors operated within.

March 6, 2026: Peptide Sciences voluntarily closes all operations. The website goes offline. Pending orders are left unfulfilled.

Why Did Peptide Sciences Shut Down?

No single event caused the closure. The convergence of factors made continued operation increasingly untenable:

Regulatory pressure: 50+ warning letters in September 2025 signaled a coordinated FDA campaign. The Amino Asylum warehouse raid in June 2025 demonstrated the FDA was willing to pursue criminal enforcement, not just letters.

Pharmaceutical litigation: Eli Lilly had already secured a January 2025 ITC order blocking tirzepatide imports. Similar actions were anticipated for semaglutide analogs — cutting off the GLP-1 product lines that drove the most revenue.

Quality control exposure: Third-party testing revealing counterfeit-flagged retatrutide samples created legal liability. If products being sold as semaglutide or tirzepatide were not what they claimed, the risk profile changed entirely.

Payment processing: Credit card processors had been declining to service research chemical vendors, forcing reliance on alternative payment methods that created additional legal risk.

The SAFE Drugs Act: Even without passing, its introduction made the legislative direction clear.

The founders appear to have calculated that voluntary closure was preferable to an Amino Asylum-style raid or Paradigm Peptides-style criminal prosecution.

What Does This Mean for Researchers?

For researchers who had pending orders with Peptide Sciences at time of closure: orders were not fulfilled and the company has not communicated about refunds. If you paid by credit card, initiate a chargeback with your card issuer.

For ongoing research that depended on Peptide Sciences products: you will need a new supplier. The key criteria that mattered about Peptide Sciences — established track record, consistent documentation, US-based shipping — still apply.

What to look for in a replacement:
– Third-party independent COA (HPLC ≥98%, mass spectrometry confirmation) — note that Peptide Sciences’ internal quality control apparently did not catch the counterfeit retatrutide samples
– GLP-1 peptide availability (semaglutide, tirzepatide, retatrutide, CagriSema)
– US domestic shipping
– Research-only positioning that complies with applicable regulations

Where to Source Research Peptides After Peptide Sciences

Life Link Research is a US-based research peptide supplier that maintains the quality standards researchers expected from Peptide Sciences — with one key upgrade: fully independent third-party COAs on every batch.

Every product includes a six-panel third-party analysis: HPLC purity (≥98%), mass spectrometry molecular weight confirmation, endotoxin testing (LAL), sterility, moisture content, and amino acid composition. COAs are available before purchase for verification — not after.

The GLP-1 and incretin peptide range covers semaglutide (10mg and 15mg), tirzepatide (15mg), retatrutide (15mg), and CagriSema (10mg) — including compounds that Peptide Sciences’ third-party testing had flagged for quality concerns.

View Life Link Research Products →

Frequently Asked Questions

Is Peptide Sciences coming back?

No. Peptide Sciences posted a permanent closure notice on March 6, 2026. There has been no indication of a planned return or relaunch under the same or a different name.

Were Peptide Sciences products safe?

This is difficult to answer definitively. For products where third-party testing showed correct molecular weight and purity (many of their catalog), products likely matched what was labeled. For retatrutide, independent testing raised significant questions about authenticity. Researchers who used Peptide Sciences products should verify their specific compounds via third-party testing if accuracy is critical to their research.

Will I get a refund for unfulfilled orders?

Peptide Sciences has not communicated about refunds. If you paid by credit card, initiate a chargeback. If you paid via cryptocurrency or ACH, recovery is significantly more difficult.

What is the best Peptide Sciences alternative?

Look for a US-based supplier with fully independent (not vendor-internal) COA documentation, a complete GLP-1 peptide range, and a track record of consistent supply. Life Link Research meets all three criteria.

Is it still legal to buy research peptides in 2026?

Research peptide sales occupy a complex legal space. Most research peptides remain legal to buy and sell for legitimate research purposes under the “research use only” framework. The SAFE Drugs Act, if passed, would restrict this for compounds identical to FDA-approved drugs. As of May 2026, the bill is in committee. Consult legal counsel for guidance specific to your research context.

For research purposes only. Life Link Research products are not for human use, clinical application, or veterinary use.